CoChat

Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Objective: The aim of this study was to investigate the renoprotective effects and molecular mechanisms of astragaloside IV (AS-IV) in streptozotocin (STZ)-induced diabetic mice. Methods: Male C57BL/6 mice were injected intraperitoneally with STZ at 200 mg/kg body weight. AS-IV was administered for 8 consecutive weeks, beginning 1 week after STZ injection. Body weight, 24-hour urinary albumin excretion, and fasting blood glucose were measured. Kidney tissues were examined by histopathological analyses. Total levels and phosphorylation of mitogen-activated protein kinase 1/2 (MEK1/2), extracellular signal-regulated kinases 1 and 2 (ERK1/2), and ribosomal S6 kinase 2 (RSK2) were determined by Western blotting analysis. Results: AS-IV treatment significantly reduced albuminuria and serum creatinine levels, ameliorated mesangial matrix expansion and greater foot process width, and decreased the levels of urinary N-acetyl-beta-D-glucosaminidase, neutrophil gelatinase-associated lipocalin, and transforming growth factor-beta 1 in STZ-induced diabetic mice. AS-IV also inhibited renal cortical phosphorylation of MEK1/2, ERK1/2 and RSK2. Conclusion: Our results suggest that AS-IV attenuates renal injury in STZ-induced diabetic mice. This effect might be partially associated with inhibition of the activation of the MEK1/2-ERK1/2-RSK2 signaling pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0300060518778711

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Astragaloside IV (AS-IV) reduced the albuminuria in diabetic mice. Effects of AS-IV on (a) urinary albumin excretion and (b) urinary albumin to creatinine ratio (UACR) after 4 and 8 weeks of treatment. Results are represented as mean ± SD (n = 6 per group). ***P < 0.001 between the control and the streptozotocin (STZ) group; #P < 0.05 and ##P < 0.01 between the STZ and the STZ+ AS-IV groups. △△△P < 0.001 between the control and the STZ+ AS-IV groups.
Figure 1. Astragaloside IV (AS-IV) reduced the albuminuria in diabetic mice. Effects of AS-IV on (a) urinary albumin excretion and (b) urinary albumin to creatinine ratio (UACR) after 4 and 8 weeks of treatment. Results are represented as mean ± SD (n = 6 per group). ***P < 0.001 between the control and the streptozotocin (STZ) group; #P < 0.05 and ##P < 0.01 between the STZ and the STZ+ AS-IV groups. △△△P < 0.001 between the control and the STZ+ AS-IV groups.CC BY-NC · PubMed Central
Figure 2. Astragaloside IV (AS-IV) had no effect on fasting blood glucose, urinary glucose and serum insulin in diabetic mice. Effects of AS-IV on blood glucose levels throughout the study (a). Effects of AS-IV on urinary glucose (b) and serum insulin (c) after 8 weeks of treatment. Results are represented as mean ± SD (n = 6 per group). ***P < 0.001 between the control and the streptozotocin (STZ) groups. △△△P < 0.001 between the control and the STZ+ AS-IV groups.
Figure 2. Astragaloside IV (AS-IV) had no effect on fasting blood glucose, urinary glucose and serum insulin in diabetic mice. Effects of AS-IV on blood glucose levels throughout the study (a). Effects of AS-IV on urinary glucose (b) and serum insulin (c) after 8 weeks of treatment. Results are represented as mean ± SD (n = 6 per group). ***P < 0.001 between the control and the streptozotocin (STZ) groups. △△△P < 0.001 between the control and the STZ+ AS-IV groups.CC BY-NC · PubMed Central
Figure 3. Astragaloside IV (AS-IV) had no effect on body weight and kidney weight in diabetic mice. Effects of AS-IV on body weight throughout the study (a). Effects of AS-IV on kidney weight after 8 weeks of treatment (b). ***P < 0.001 between the control and the streptozotocin (STZ) groups. △P < 0.05 and △△△P < 0.001 between the control and the STZ+ AS-IV groups.
Figure 3. Astragaloside IV (AS-IV) had no effect on body weight and kidney weight in diabetic mice. Effects of AS-IV on body weight throughout the study (a). Effects of AS-IV on kidney weight after 8 weeks of treatment (b). ***P < 0.001 between the control and the streptozotocin (STZ) groups. △P < 0.05 and △△△P < 0.001 between the control and the STZ+ AS-IV groups.CC BY-NC · PubMed Central
Figure 4. Astragaloside IV (AS-IV) attenuated glomerular tuft areas (GTA), mesangial matrix and foot process width (FPW), but did not affect glomerular basement membranes (GBM) in diabetic mice. Effects of AS-IV on GTA (a), mesangial matrix (b), GBM (c) and FPW (d) after 8 weeks of treatment. Periodic acid-Schiff (PAS) staining and electron microscopy (EM) images were used to depict these characteristics for each group (e). Scale bars, 25 µm for PAS images, 200 nm for EM. Results are represented as mean ± SD (n = 3–6 per group). *P < 0.05 and **P < 0.01 between the control and the streptozotocin (STZ) group. #P < 0.05 between the STZ and the STZ+ AS-IV groups. △P < 0.05 between the control and the STZ+ AS-IV groups.
Figure 4. Astragaloside IV (AS-IV) attenuated glomerular tuft areas (GTA), mesangial matrix and foot process width (FPW), but did not affect glomerular basement membranes (GBM) in diabetic mice. Effects of AS-IV on GTA (a), mesangial matrix (b), GBM (c) and FPW (d) after 8 weeks of treatment. Periodic acid-Schiff (PAS) staining and electron microscopy (EM) images were used to depict these characteristics for each group (e). Scale bars, 25 µm for PAS images, 200 nm for EM. Results are represented as mean ± SD (n = 3–6 per group). *P < 0.05 and **P < 0.01 between the control and the streptozotocin (STZ) group. #P < 0.05 between the STZ and the STZ+ AS-IV groups. △P < 0.05 between the control and the STZ+ AS-IV groups.CC BY-NC · PubMed Central
Figure 5. Astragaloside IV (AS-IV) decreased urinary N-acetyl-beta-D-glucosaminidase (NGAL), neutrophil gelatinase-associated lipocalin (NAG) and transforming growth factor-beta 1 (TGF-β1) in diabetic mice, reduced proximal tubular area, but did not affect proximal tubular lumen area and tubular basement membranes (TBM). Effects of AS-IV on urinary NGAL (a), NAG (b), TGF-β1 (c), proximal tubular area (d), proximal tubular lumen area (e) and TBM (f) after 8 weeks of treatment. The representative images of tubular periodic acid-Schiff (PAS) staining and TBM are shown in g. Scale bars, 25 µm for PAS images, 200 nm for electron microscopy (EM). Data are represented as mean ± SD (n = 3–6 per group). *P < 0.05 and ***P < 0.001 between the control and the streptozotocin (STZ) group. #P < 0.05 between the STZ and the STZ+ AS-IV groups. △P < 0.05 and △△△P < 0.001 between the control and the STZ+ AS-IV groups.
Figure 5. Astragaloside IV (AS-IV) decreased urinary N-acetyl-beta-D-glucosaminidase (NGAL), neutrophil gelatinase-associated lipocalin (NAG) and transforming growth factor-beta 1 (TGF-β1) in diabetic mice, reduced proximal tubular area, but did not affect proximal tubular lumen area and tubular basement membranes (TBM). Effects of AS-IV on urinary NGAL (a), NAG (b), TGF-β1 (c), proximal tubular area (d), proximal tubular lumen area (e) and TBM (f) after 8 weeks of treatment. The representative images of tubular periodic acid-Schiff (PAS) staining and TBM are shown in g. Scale bars, 25 µm for PAS images, 200 nm for electron microscopy (EM). Data are represented as mean ± SD (n = 3–6 per group). *P < 0.05 and ***P < 0.001 between the control and the streptozotocin (STZ) group. #P < 0.05 between the STZ and the STZ+ AS-IV groups. △P < 0.05 and △△△P < 0.001 between the control and the STZ+ AS-IV groups.CC BY-NC · PubMed Central
Figure 6. Astragaloside IV (AS-IV) inhibited the activation of MEK1/2, ERK1/2 and RSK2 in the renal cortex of diabetic mice. Effects of AS-IV on the expression of p-MEK1/2 (b), p-ERK1/2 (d), and p-RSK2 (f) in the renal cortex of diabetic mice after 8 weeks of treatment. Representative western blots are shown for total and phosphorylated MEK1/2 (a), ERK1/2 (c) and RSK2 (e). Data are represented as mean ± SD (n = 4 per group). **P < 0.01 between the control and the streptozotocin (STZ) group. ##P < 0.01 between the STZ and the STZ+AS-IV groups.
Figure 6. Astragaloside IV (AS-IV) inhibited the activation of MEK1/2, ERK1/2 and RSK2 in the renal cortex of diabetic mice. Effects of AS-IV on the expression of p-MEK1/2 (b), p-ERK1/2 (d), and p-RSK2 (f) in the renal cortex of diabetic mice after 8 weeks of treatment. Representative western blots are shown for total and phosphorylated MEK1/2 (a), ERK1/2 (c) and RSK2 (e). Data are represented as mean ± SD (n = 4 per group). **P < 0.01 between the control and the streptozotocin (STZ) group. ##P < 0.01 between the STZ and the STZ+AS-IV groups.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 35

Metadata

Authors
Song, G., Han, P., Sun, H., Shao, M., Yu, X., Wang, W., Wang, D., Yi, W., Ge, N., Li, S., & Yi, T.
Affiliations
Guangzhou University of Chinese Medicine (CN)
Corresponding author
Yi, Tiegang
Venue
Journal of International Medical Research
Published
2018-06-13
Volume
46
Issue
7
Pages
2883-2897
ISSN
  • 0300-0605 (ISSN-L)
  • 1473-2300
OpenAlex
W2808372909
Cited by
34
References
52
Citations by year
2026: 4 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 5 · 2020: 5 · 2019: 6
FWCI
3.27
Type
journal article
Language
en
Open access
Locations
  • Journal of International Medical Research (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81373565, 81673794)
  • Natural Science Foundation of Guangdong Province (2015A030313883)
  • Shenzhen Science and Technology Project (JCYJ20150401163247228, JCYJ20160330171116798)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Complementary and alternative medicine › Traditional Chinese Medicine Analysis
Keywords
astragaloside IV, diabetic nephropathy, renal protection, streptozotocin-induced diabetes, albuminuria, mesangial expansion, neutrophil gelatinase-associated lipocalin, TGF-β1, MAPK signaling
MeSH terms
Animals, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Drugs, Chinese Herbal, Kidney, Male, Mice, Inbred C57BL, Saponins, Triterpenes, Protective Agents, MAP Kinase Signaling System, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice. https://app.cochat.ai/papers/10.1177/0300060518778711
The paper
Song, G., Han, P., Sun, H., Shao, M., Yu, X., Wang, W., Wang, D., Yi, W., Ge, N., Li, S., & Yi, T. (2018). Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice. Journal of International Medical Research. https://doi.org/10.1177/0300060518778711

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.